Navigation Links
HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Date:6/12/2012

CHARLOTTESVILLE, Va., June 12, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, announced today that they have published a key Review article entitled, Organotypic systems in drug metabolism and toxicity: challenges and opportunities, in Expert Opin. Drug Metab. Toxicol. Authored by Ajit Dash, MD, PhD and HemoShear co-founders Brett R. Blackman, PhD and Brian R. Wamhoff, PhD, this Expert Opinion examines the various approaches to recreating meaningful human biology on the bench and traces the evolution of organotypic systems while discussing intrinsic challenges and opportunities that lie ahead. Furthermore, they cite literature that is the foundation of several biotechnology research companies addressing this issue and discuss major government-funded initiatives to aid the development of these systems.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

"High-throughput screening cell-based tools still serve a purpose in compound screening campaigns, but they continue to fail in predicting in vivo response for important and costly pipeline decisions," said Dr. Dash, Director of HemoShear's Liver Surrogate Systems Division. "Further, the limitations of animal models in predicting human safety or drug efficacy continue to negatively impact drug companies' confidence as they make important decisions about whether to enter human clinical trials."

"Our vision as a company is to develop meaningful human-relevant systems so that we can help our biopharmaceutical partners make more meaningful decisions in their pre-clinical pipelines, greatly reducing the risk in their portfolio," said Dr. Wamhoff. "Initial results in our vascular and liver surrogate systems indicate that we can recreate human in vivo biology and response on the bench, which is extremely exciting! Continued development and validation of these systems and disease systems is important to our partners. The science is groundbreaking and the data human-relevant.  We really are thinking about drug discovery from the human perspective."

About HemoShear, LLC
HemoShear LLC is a biotechnology research company that combines its scientific expertise with its proprietary platform technology in research collaborations with pharmaceutical companies to accelerate drug discovery and development. HemoShear has expertise in the areas of human and animal biology, bioinformatics and molecular profiling for target identification and validation, cell-signaling pathway analysis, sophisticated methods to quantify target genes and proteins, assessment of molecular pharmacology, and methods to determine mechanisms of action for drug efficacy and safety.

HemoShear's technology platform can be adapted to replicate the biology of human or animal organ systems in both healthy and disease-prone states by applying physiologically accurate hemodynamic forces to primary cell cultures.  HemoShear is currently collaborating with several large pharmaceutical companies on programs that span the drug discovery and development spectrum.  HemoShear is a privately held company located in Charlottesville, Virginia.  To learn more about HemoShear and our research, please visit our website at www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
4. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
5. Delcath Systems, Inc. Secures $20 Million Credit Facility
6. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
9. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
10. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
11. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
Breaking Medicine News(10 mins):